Nivolumab,Relatlimab
bms
['nsclc', 'sclc', 'opdivo', 'opdualag', 'biomarker', 'marker ', 'bms']
bms' combo drug opdualag effective in neoadjuvant nsclc, but maybe no better than opdivo alone. esmo data show the immunotherapy combo was feasible and safe pre-surgery, but biomarker analyses are needed to see if subgroups benefit more from opdualag... 